PGNY News and Press, Progyny Inc. From 04/15/21

Stocks are on the move after hours following the most recent changes from S&P Dow Jones Indices, starting with PTC. Currently a constituent of the S&P MidCap 400, PTC will move into the S&P 500 to replace Varian Medical Systems (VAR), which was acquired today by Siemens Healthinee...

Gainers: [[PGNY]] +7.9%. [[XELB]] +7.0%. [[IDYA]] +6.9%. [[LSCC]] +6.6%. [[DKNG]] +6.0%.Losers: [[SPNE]] -3.8%. [[DBVT]] -3.4%. [[SYBX]] -3.0%. [[SESN]] -2.6%. [[DSEY]] -2.5%. For further details see: PGNY, XELB, SPNE and SYBX among after-hours movers

Progyny ([[PGNY]] +5.3%) shares have surged ~89.4% over the past 12-month period. Yet the analysts at Bank of America have upgraded the stock to buy from neutral noting an ‘attractive’ entry point following the recent pullback.At ~7x 2022 EV/ revenue estimate, the price target i...

Progyny shares fall ([[PGNY]] -8.2%) after the company posted fourth-quarter results and disclosed its full-year forecast for 2021.Q4 revenue of $100.3M (+54.0% Y/Y), beats by $2.44M.2021 guidance: Revenue is projected to be $520M to $540M; Net income is projected to be $30.1M to $37.4M, or $...

Progyny, Inc. (PGNY) Q4 2020 Earnings Conference Call February 24, 2021, 04:45 PM ET Company Participants James Hart - Vice President of Investor Relations David Schlanger - Chief Executive Officer Pete Anevski - Chief Operating Officer Mark Livingston - Chief Financial Officer Conference Cal...

Progyny (PGNY): Q4 EPS of $0.07 may not be comparable to consensus of $0.07.Revenue of $100.3M (+54.0% Y/Y) beats by $2.44M.Press Release For further details see: Progyny EPS of $0.07

Reports Record Fourth Quarter Revenue of $100.3 Million Issues Revenue Guidance of $520.0 to $540.0 Million for 2021, Reflecting Growth of 51% to 57% NEW YORK, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertili...

[[ACA]], [[ACAD]], [[ADPT]], [[AGI]], [[AMED]], [[ANSS]], [[APA]], [[AWK]], [[BILI]], [[BKNG]], [[CCRN]], [[CDNA]], [[CHDN]], [[CNXN]], [[CW]], [[DDD]], [[DOOR]], [[DRH]], [[ECPG]], [[EPR]], [[ESI]], [[ESTC]], [[FATE]], [[FNF]], [[FTI]], [[GBT]], [[GEF]], [[GH]], [[HCC]], [[ICLR]], [[INGN]], ...

NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, today announced that David Schlanger, Progyny’s Chief Executive Officer, and Mark Liv...

Progyny (NASDAQ: PGNY) is a recent healthcare IPO that aims to revolutionize the fertility industry. And with a market cap of just over $4 billion, it could still have a long way to grow in a huge market that's just begging to be disrupted. In this Jan. 7 Fool Live clip, Fool.co...